Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

<p>NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) &#8212; Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board. “We are absolutely thrilled that Clay [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/tourmaline-bio-appoints-dr-clay-siegall-as-chairman-of-the-board/">Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>